Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab

Research output: Contribution to journalArticle

Abstract

The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

Original languageItalian
Pages (from-to)414-7
Number of pages4
JournalRecenti Progressi in Medicina
Volume107
Issue number8
DOIs
Publication statusPublished - Aug 2016

Fingerprint

Immunotherapy
Melanoma
Survival Rate
Safety
Natural History
nivolumab
Therapeutics

Keywords

  • English Abstract
  • Journal Article

Cite this

@article{99abfe6a952941a5b77db913b33e5fbd,
title = "Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab",
abstract = "The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42{\%} at 3 years and with an overall survival rate of 35{\%} at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.",
keywords = "English Abstract, Journal Article",
author = "{Del Vecchio}, Michele",
year = "2016",
month = "8",
doi = "10.1701/2332.25062",
language = "Italian",
volume = "107",
pages = "414--7",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "8",

}

TY - JOUR

T1 - Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

AU - Del Vecchio, Michele

PY - 2016/8

Y1 - 2016/8

N2 - The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

AB - The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

KW - English Abstract

KW - Journal Article

U2 - 10.1701/2332.25062

DO - 10.1701/2332.25062

M3 - Articolo

VL - 107

SP - 414

EP - 417

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 8

ER -